Stallergenes and DBV Technologies Announce Respiratory Allergy Research and Development Collaboration for Birch Pollen
  • Stallergenes to exercise option to develop and commercialize a birch allergy new product 
  • DBV eligible for milestone payments and royalties on Stallergenes’ net sales 
  • Stallergenes acquires an equity position in DBV 

ANTONY and BAGNEUX, France, 18 October 2013 Stallergenes S.A. (Euronext Paris: GENP), worldwide leader in allergen immunotherapy, and DBV Technologies (Euronext Paris: DBV), creator of Viaskin® for the treatment of allergies, announced today that they have entered into a research and development agreement for the treatment of birch allergy. This collaboration is the first agreement following their previously announced collaboration focused on developing innovative treatments for respiratory allergies. This partnership combines Stallergenes’ world class respiratory allergy know-how with DBV’s novel Viaskin® epicutaneous delivery technology that modulates the immune response to allergens.

 

To download the full version of the Press Release in English language, please click on the following link:
Stallergenes and DBV Technologies Announce Respiratory Allergy partner